In this contribution, we have designed and developed nanovehicles from poly(ethylene glycol)‐b‐poly(l‐boronophenylalanine‐co‐l‐tyrosine) (PEG‐b‐P(BPA‐co‐Tyr)) for efficient coencapsulation and responsive release of both BCL2 (ABT199) and MCL1 (TW37) inhibitors, achieving synergetic and potent treatment of AML (Scheme 1). Here, MCL1 is linked to acute myeloid leukemia.